The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | AML18 trial: fractionated vs single dose of gemtuzumab ozogamicin in older patients with AML
Nigel Russell, MD, Guy’s Hospital NHS Trust, London, UK, shares the results of the AML18 trial (NCT02272478), which evaluated a single versus a fractionated schedule of gemtuzumab ozogamicin (GO) in combination with daunorubicin/cytarabine (DA) as induction therapy in older patients with acute myeloid leukemia (AML). Overall, it was observed that the fractionated schedule resulted in a better measurable residual disease (MRD) response and was associated with improved survival. In addition, patients who went on to receive an allogeneic transplant had better outcomes with the fractionated GO schedule. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer: Honoraria, Research Funding, Speakers Bureau; Astellas: Honoraria; Jazz Pharma: Research Funding; Servier: Honoraria.
